Image

Global Cyclic Heavy Menstrual Bleeding Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Cyclic Heavy Menstrual Bleeding Market, By Type (Polymenorrhea, Oligomenorrhea, Metrorrhagia), By Treatment Type (Medication, Hormonal Therapy, Surgery), By Route of Administration Type (Oral and Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Cyclic Heavy Menstrual Bleeding Market

Cyclic Heavy Menstrual Bleeding Market Analysis and Size

Heavy menstrual bleeding (HMB) is one of the most common debilitating gynecologic disorders that is affecting women of reproductive age. Increasing incidence rate drives the growth of the cyclic heavy menstrual bleeding market. Rising cases of uterine fibroids and polyps boost the growth of cyclic heavy menstrual bleeding. In addition, effective treatment cost and easy availability of treatment options plays a significant role in the market growth in the above-forecasted period.

Data Bridge Market Research analyses a growth rate in the global cyclic heavy menstrual bleeding market in the forecast period 2023-2030. The expected CAGR of the global cyclic heavy menstrual bleeding market is around 5.50% in the forecast period. The market was valued at USD 40.3 billion in 2022, and it would grow up to USD 61.85 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Cyclic Heavy Menstrual Bleeding Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Polymenorrhea, Oligomenorrhea, Metrorrhagia), By Treatment Type (Medication, Hormonal Therapy,  Surgery), By Route of Administration Type (Oral and Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc.(U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (U.S.), AstraZeneca (India), Zimmer Biomet (U.S.), Clover Health Care Pharma (India), CSL Limited (Australia), Ferring B.V. (Switzerland)

Market Opportunities

  • Presence of Higher Alternatives
  • Increasing Demand for Retail Pharmacies

Market Definition

Cyclic heavy menstrual bleeding also known as menorrhagia is the most common type of abnormal uterine bleeding. It is usually characterized by excessively prolonged and heavy menstrual bleeding at regular menstrual cycle intervals. Numerous factors, such as hormonal imbalance, ovaries dysfunction, uterine fibroids, polyps, adenomyosis, and others, cause it.  

Global Cyclic Heavy Menstrual Bleeding Market Dynamics

Drivers

  • Increase in Elderly Population

As per different surveys, the elderly population is more vulnerable to suffering from this disease. According to the Aging World reports from 2015, there were about 562 million people 65 and older worldwide, which increased the disease incidence and fuelled the market's growth.

  • Increase in the Number of R&D Activities      

An increase in the number of R&D activities boosts the market growth. This will benefit the global cyclic heavy menstrual bleeding market. The government funds research and development (R&D) initiatives to motivate researchers and pharmaceutical companies to develop novel medicines.

Opportunities

  • Presence of Higher Alternatives

Several treatment alternatives are available, such as pharmacological or surgical treatment. Pharmacological options include non-steroidal anti-inflammatory drugs (NSAIDs), hormonal therapies, birth control pills, gonadotropin-releasing hormone (GnRH) agonists, and antifibrinolytic medicines are also available that help in the growth of the market.

  • Increasing Demand for Retail Pharmacies

An increase in the number of drugs used for the global cyclic heavy menstrual bleeding market being delivered through retail pharmacies and a rise in the number of retail pharmacies in highly developed countries create opportunities for market growth. In addition, patients prefer retail pharmacies for purchasing drugs, as these are easily available.

Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified healthcare professionals who cannot perform these treatments could reduce the global cyclic heavy menstrual bleeding market growth during the forecast period.

  • Development of Complications

Often, patients aid in the treatment process themselves, creating complications. Treatment without proper consultation with the doctor is dangerous and negatively impacts the patients. All these factors restrict the growth of the market.

This global cyclic heavy menstrual bleeding market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cyclic heavy menstrual bleeding market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Cyclic Heavy Menstrual Bleeding Market Scope

The global cyclic heavy menstrual bleeding market is segmented on the basis of causes, symptoms, diagnosis, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Causes

  • Polymenorrhea
  • Oligomenorrhea
  • Metrorrhagia

Treatment Type

  • Medication
  • Hormonal Therapy
  • Surgery

Route of Administration

  • Oral
  • Parenteral

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Global Cyclic Heavy Menstrual Bleeding Market Regional Analysis/Insights

The global cyclic heavy menstrual bleeding market is analysed and market size insights and trends are provided by causes, symptoms, diagnosis, distribution channel and end-user as referenced above.

The major countries covered in the global cyclic heavy menstrual bleeding market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for the global cyclic heavy menstrual bleeding market throughout the forecasted period due to the huge patient population and the presence of huge opportunities in this region.

North America dominates the market because of the continuous change in lifestyle and increasing healthcare expenditure, huge patient population, increasing healthcare expenditures, well-developed healthcare sector, and government support for R&D in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Cyclic Heavy Menstrual Bleeding Market Share Analysis

The global cyclic heavy menstrual bleeding market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global cyclic heavy menstrual bleeding market

Key players operating in the global cyclic heavy menstrual bleeding market include:

  • Pfizer Inc.(U.S.)
  • Merck KGaA (Germany)
  • Sanofi (France)
  • Biocare Medical, LLC (U.S.)
  • Lilly (U.S.)
  • Teva Pharmaceutical Industries (Israel)
  • Bristol-Myers Squibb Company (U.S.)
  • GSK plc. (U.K.)
  • Bayer AG (U.S.)
  • AstraZeneca (India)
  • Zimmer Biomet (U.S.)
  • Clover Health Care Pharma (India)
  • CSL Limited (Australia)
  • Ferring B.V. (Switzerland


SKU-
Why Choose Us


Frequently Asked Questions

Cyclic Heavy Menstrual Bleeding Market to grow at a CAGR 5.50% by forecast 2030.
Cyclic Heavy Menstrual Bleeding Market value to reach 61.85 billion by forecast 2030.
The major countries covered in the global cyclic heavy menstrual bleeding market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Major players operating in the global cyclic heavy menstrual bleeding market are: Pfizer Inc.(U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (U.S.), AstraZeneca (India), Zimmer Biomet (U.S.), Clover Health Care Pharma (India), CSL Limited (Australia).